Get started
Work

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma

Year: 2020
Type: article
Abstract: In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In 2019, conditional approvals were granted by Health Canada and the European Commission for the same indications. Limited data exist pertaining to the clinical characteristics, disease progression and survivorship of patients with advanced CSCC in real-world clinical practice. CemiplimAb-rwlc Survivorship and Epidemiology (CASE) is a prospective Phase IV, noninterventional, survivorship and epidemiology study that will enroll patients with advanced CSCC who have recently initiated or who plan to receive cemiplimab in a real-world setting. Trial registration number: NCT03836105.
DOI: 10.2217/fon-2019-0762
Authors: Michael R Migden, Sunandana Chandra, Guilherme Rabinowits, Chieh-I Chen, Jigar Desai, Alex Seluzhytsky, Medha Sasane, Benedetta Campanelli, Zhen Chen, Morganna L Freeman, Sherrif F Ibrahim, Nikhil I Khushalani, Michael Andria, Emily Ruiz
Institutions: The University of Texas MD Anderson Cancer Center, Northwestern University, Baptist Hospital of Miami, Baptist Health South Florida, Regeneron (United States), Sanofi (United States), City Of Hope National Medical Center, City of Hope, University of Rochester Medicine, Moffitt Cancer Center, Brigham and Women's Hospital, Harvard University
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W3000739799
FWCI: 5.312
Cites: 17
Cited by: 39
Related to: 10